« Back
Home /
Crizotinib (hydrochloride)

Crizotinib (hydrochloride)

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Molecular Targets for Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Lymphatic System Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	50 mg
Item no.	HY-50878A-50mg
Targets	MET, ALK
CASRN	1415560-69-8
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	486.80
Clinical_Information	Launched
Manufacturers Research_Area	Cancer
Solubility	DMSO : ≥ 4.9 mg/mL\|H2O : 50 mg/mL (ultrasonic)
Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50878A-50mg-safety-datasheet.pdf